secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001193125-26-144582
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001
----------------------------------------------------------------

- First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).
- Part A: ~140 patients, primary endpoint change in PVR at Week 24, double-blind placebo-controlled.
- Part B: ~346 patients, primary endpoint change in 6MWD at Week 24, seamless transition from Part A.
- Adaptive design includes a 12-week dose-titration phase; FDA confirmed study plan.
- Trial to be conducted at up to ~180 sites worldwide; NDA filing timeline accelerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526144582/0001193125-26-144582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526144582/d108350d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-144582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer